CORE--VECTOR CONSTRUCTION

VECTOR CONSTRUTION CORE将支持以下产品的临床前评价 通过促进设计和构建反式显性突变蛋白 逆转录病毒-腺病毒和非病毒载体， 基因的有效和安全的细胞内递送。Nabel博士 密歇根大学将是该核心的主任，并与博士。 巴克罗斯勒博士和Chevien女士，他在牛津大学的工作人员， 密歇根大学，将监督表达质粒DNA的纯化， 提供腺病毒基因组骨架，产生重组 克隆，重组腺病毒的大规模纯化， 重组逆转录病毒的构建和纯化。的目标 载体建设的核心是：（1）提供集中的核心实验室 用于重组的构建、纯化和表征 含有与HIV-1研究相关的基因的载体， 体外和体内基因转移试剂。这些系统包括非- 病毒（表达质粒）和病毒（重组逆转录病毒和 重组腺病毒）技术;和（2）提供改善的获得 与这些基因转移系统的使用相关的技术。的 载体构建核心具有适当的设施并建立 质量控制测试的详细文档程序，以确保 载体制备过程中的生产重现性 药物非临床研究质量管理规范（GLP）以及药品生产质量管理规范 (GMP)FDA指南，使载体适用于人类 临床试验将这些材料包装和运输至 要求研究者按照既定CDC进行 指南和FDA法规。载体构建核心便于 研究人员之间的互动，使研究人员能够随时访问 重组载体系统，降低了这项技术的成本， 个人调查员，并通过以下方式促进新项目的启动 帮助载体设计和方案开发。

The VECTOR CONSTRUCTION CORE will support the preclinical evaluation of transdominant mutant proteins by facilitating the design and construction of retrovirus-adenovirus-and non-viral-based vectors to allow more efficient and safe intracellular delivery of the genes. Dr. Nabel of the University of Michigan will be the director of the core and with Dr. Barker. Dr. Roessler and Ms. Chevien, his staff at the University of Michigan, will oversee the purification of expression plasmid DNA, the provision of adenoviral genomic backbones, the generation of recombinant clones, large-scale purification of recombinant adenovirus and construction and purification of recombinant retrovirus. The goal of the vector construction core is to: (1) provide a centralized core laboratory for the construction, purification and characterization of recombinant vectors containing genes relevant to the study of HIV-1 for use as in vitro and in vivo gene transfer reagents. These systems include both non- viral (expression plasmid) and viral (recombinant retrovirus and recombinant adenovirus) technologies; and (2) provide improved access to the technology associated with the use of these gene transfer systems. The vector construction core has the appropriate facilities and established programs for detailed documentation for quality control tests to assure reproducibility of production during vector preparation required under Good Laboratory Practice (GLP) as well as Good Manufacturing Practice (GMP) FDA guidelines so that vectors are suitable for use in human clinical trials. Packaging and shipping of these materials to the requesting investigator will be done in accordance with established CDC guidelines and FDA regulations. The vector construction core facilitates interactions among investigators, allows investigators to readily access recombinant vector systems, lowers the cost of this technology to individual investigators and facilitates the initiation of new projects by aiding in vector design and protocol development.